1. Home
  2. BGLC vs ALZN Comparison

BGLC vs ALZN Comparison

Compare BGLC & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • ALZN
  • Stock Information
  • Founded
  • BGLC 2017
  • ALZN 2016
  • Country
  • BGLC Malaysia
  • ALZN United States
  • Employees
  • BGLC N/A
  • ALZN N/A
  • Industry
  • BGLC Medical Specialities
  • ALZN Medicinal Chemicals and Botanical Products
  • Sector
  • BGLC Health Care
  • ALZN Health Care
  • Exchange
  • BGLC Nasdaq
  • ALZN Nasdaq
  • Market Cap
  • BGLC 7.6M
  • ALZN 7.0M
  • IPO Year
  • BGLC N/A
  • ALZN 2021
  • Fundamental
  • Price
  • BGLC $0.30
  • ALZN $1.37
  • Analyst Decision
  • BGLC
  • ALZN Strong Buy
  • Analyst Count
  • BGLC 0
  • ALZN 1
  • Target Price
  • BGLC N/A
  • ALZN $35.00
  • AVG Volume (30 Days)
  • BGLC 78.2K
  • ALZN 128.2K
  • Earning Date
  • BGLC 11-20-2024
  • ALZN 12-13-2024
  • Dividend Yield
  • BGLC N/A
  • ALZN N/A
  • EPS Growth
  • BGLC N/A
  • ALZN N/A
  • EPS
  • BGLC N/A
  • ALZN N/A
  • Revenue
  • BGLC $9,183,168.00
  • ALZN N/A
  • Revenue This Year
  • BGLC N/A
  • ALZN N/A
  • Revenue Next Year
  • BGLC N/A
  • ALZN N/A
  • P/E Ratio
  • BGLC N/A
  • ALZN N/A
  • Revenue Growth
  • BGLC N/A
  • ALZN N/A
  • 52 Week Low
  • BGLC $0.31
  • ALZN $1.40
  • 52 Week High
  • BGLC $3.39
  • ALZN $19.20
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 28.91
  • ALZN 38.66
  • Support Level
  • BGLC $0.32
  • ALZN $1.43
  • Resistance Level
  • BGLC $0.38
  • ALZN $1.59
  • Average True Range (ATR)
  • BGLC 0.02
  • ALZN 0.09
  • MACD
  • BGLC -0.00
  • ALZN 0.00
  • Stochastic Oscillator
  • BGLC 0.00
  • ALZN 15.38

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Share on Social Networks: